Electrocore Inc ECOR

$10.14 -0.17 (-1.70%)

Valuation

Market cap
91,421,000
Revenue TTM
$32,030,000
Net income TTM
$-13,970,000
PE ratio
0.00
Forward PE
—
Profit margin
-43.62%
Debt to equity
-2.07

Trading

Volume
122,200
Avg volume
88,914
Day's range
$9.92 – $11.02
Shares out
9,016,000
Stochastic %K
8%
Beta
1.05
Analysts
Strong Sell
Price target
$18.96

Price

Company profile

electroCore, Inc., a bioelectronic technology medicine and general wellness company, provides non-invasive vagus nerve stimulation (nVNS) technology platform in the United States, the United Kingdom, and internationally. The company develops gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic cluster headache, as...

Show more

electroCore, Inc., a bioelectronic technology medicine and general wellness company, provides non-invasive vagus nerve stimulation (nVNS) technology platform in the United States, the United Kingdom, and internationally. The company develops gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for the treatment of hemicrania continua and paroxysmal hemicrania. It also develops Truvaga 350, a personal use consumer electronics general wellness product and Truvaga Plus, an app-enabled general wellness product. It also offers non-invasive bioelectronic therapies for the treatment of chronic pain and wellness conditions. In addition, the company offers TAC-STIM for human performance and gammaCore Sapphire, a portable, reusable, rechargeable, and reloadable prescription medical device for various primary headache conditions. electroCore, Inc. was incorporated in 2005 and is headquartered in Rockaway, New Jersey.

Industry
Medical Devices
Sector
Healthcare
Phone
888 903 2673
Website
https://www.electrocore.com
Address
200 Forge Way, Suite 205, Rockaway, United States

Latest news

No headlines yet.